MX9306704A - Quinuclidinas substituidas. - Google Patents

Quinuclidinas substituidas.

Info

Publication number
MX9306704A
MX9306704A MX9306704A MX9306704A MX9306704A MX 9306704 A MX9306704 A MX 9306704A MX 9306704 A MX9306704 A MX 9306704A MX 9306704 A MX9306704 A MX 9306704A MX 9306704 A MX9306704 A MX 9306704A
Authority
MX
Mexico
Prior art keywords
carbon atoms
alkyl
substituted
halogen
alkanoylamino
Prior art date
Application number
MX9306704A
Other languages
English (en)
Inventor
Fumitaka Ito
Toshihide Kokura
Masami Nakane
Kunio Satake
Hiroaki Wakabayashi
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of MX9306704A publication Critical patent/MX9306704A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

Determinados nuevos compuestos quinuclidina sustituidos tienen lacapacidad de antagonizar la sustancia P y tienen la siguiente fórmula quese caracteriza porque Ar1 y AR2 son cada uno, independientemente, tienilo,fenilo, fluorofenilo, clorofenilo o bromofenilo; X es -CONR3R4, -CO2R3,-CH2OR3, -CH2NR3R4 o CONR3OR4; R1, R3 y R4 son cada uno,independientemente, hidrógeno o un alquilo que tiene de 1 a 4 átomos decarbono; R2 es un alquilo que tiene de 1 a 4 átomos de carbono; Y es unalquilsulfonilo que tiene de 1 a 4 átomos de carbono, unN-alquil-N-alcanoilamino (que podría estar sustituido por un halógeno enel resto alcanoilo) que tiene de 1 a 4 átomos de carbono en los restosalquilo y alcanoilo, un N-alquilsulfonilamino (que podría estar sustituidopor un halógeno en el resto alquilsulfonilo) que tiene de 1 a 4 átomos decarbono en los restos alquilo y alquilsulfonilo, un alquenilo que tiene de2 a 4 átomos de carbono, un alquinilo que tiene 2 a 4 átomos de carbono,un alquilo halosustituido que tiene de 1 a 4 átomos de carbono, unalquilamino que tiene de 1 a 4 átomos de carbono, un alcanoilamino (quepodría estar sustituido por un halógeno) que tiene de 1 a 4 átomos decarbono o un alquilsulfonilamino (que podría estar sustituido por unhalógeno) que tiene de 1 a 4 átomos de carbono. Estos compuestos sonútiles en el tratamiento de trastornos gastrointestinales o del sistemanervioso central y en el alivio de enfermedades inflamatorias, asma, dolory migraña en mamíferos y como ingrediente activo en composicionesfarmacéuticas para tratar tales estados.
MX9306704A 1992-10-28 1993-10-27 Quinuclidinas substituidas. MX9306704A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP4290569A JP2656700B2 (ja) 1992-10-28 1992-10-28 置換キヌクリジン誘導体

Publications (1)

Publication Number Publication Date
MX9306704A true MX9306704A (es) 1995-01-31

Family

ID=17757724

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9306704A MX9306704A (es) 1992-10-28 1993-10-27 Quinuclidinas substituidas.

Country Status (14)

Country Link
EP (1) EP0665843B1 (es)
JP (1) JP2656700B2 (es)
AT (1) ATE247113T1 (es)
AU (1) AU5141293A (es)
CA (1) CA2146007C (es)
DE (1) DE69333143T2 (es)
DK (1) DK0665843T3 (es)
ES (1) ES2202313T3 (es)
FI (1) FI114637B (es)
HU (1) HUT65831A (es)
IL (1) IL107346A0 (es)
MX (1) MX9306704A (es)
PT (1) PT665843E (es)
WO (1) WO1994010170A1 (es)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL109646A0 (en) * 1993-05-19 1994-08-26 Pfizer Heteroatom substituted alkyl benzylamino-quinuclidines
ES2121213T3 (es) * 1993-07-15 1998-11-16 Pfizer Benciloxiquinuclidinas como antagonistas de la sustancia p.
PT719253E (pt) * 1993-09-17 2004-07-30 Pfizer Piperidinas 3-amino-5-carboxi-substituidas e pirrolidinas 3-amino-4-carboxi-substituidas como antagonistas de taquicinina
US6083943A (en) * 1993-09-17 2000-07-04 Pfizer Inc Substituted azaheterocyclecarboxylic acid
CA2205016A1 (en) * 1994-11-10 1996-05-23 Hans-Jurgen Ernst Hess Nk-1 receptor antagonists for the treatment of eye disorders
MX9706944A (es) * 1996-09-12 1998-08-30 Pfizer Quinuclidinas sustituidas con tetrazolilo como antagonistas de la sustancia p.
US6861526B2 (en) 2002-10-16 2005-03-01 Pfizer Inc. Process for the preparation of (S,S)-cis-2-benzhydryl-3-benzylaminoquinuclidine
ZA200701232B (en) 2004-07-15 2008-08-27 Amr Technology Inc Aryl-and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine and serotonin
ES2382814T3 (es) 2005-05-17 2012-06-13 Merck Sharp & Dohme Ltd. Ácido cis-4-[(4-clorofenil)sulfonil]-4-(2,5-difluorofenil)ciclohexanopropanoico para el tratamiento del cáncer
EP1904069B1 (en) 2005-07-15 2018-06-13 Albany Molecular Research, Inc. Aryl-and heteroaryl-substituted tetrahydrobenzazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
US8293900B2 (en) 2005-09-29 2012-10-23 Merck Sharp & Dohme Corp Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators
GB0603041D0 (en) 2006-02-15 2006-03-29 Angeletti P Ist Richerche Bio Therapeutic compounds
CA2664113C (en) 2006-09-22 2013-05-28 Merck & Co., Inc. Use of platencin and platensimycin as fatty acid synthesis inhibitors to treat obesity, diabetes and cancer
US20110218176A1 (en) 2006-11-01 2011-09-08 Barbara Brooke Jennings-Spring Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
BRPI0806245B1 (pt) 2007-01-10 2022-01-25 Msd Italia S.R.L. Compostos de fórmula i e seus usos
CA2682727C (en) 2007-04-02 2016-03-22 Banyu Pharmaceutical Co., Ltd. Indoledione derivative
EP2170076B1 (en) 2007-06-27 2016-05-18 Merck Sharp & Dohme Corp. 4-carboxybenzylamino derivatives as histone deacetylase inhibitors
US8598184B2 (en) 2008-03-03 2013-12-03 Tiger Pharmatech Protein kinase inhibitors
US9156812B2 (en) 2008-06-04 2015-10-13 Bristol-Myers Squibb Company Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine
US8691825B2 (en) 2009-04-01 2014-04-08 Merck Sharp & Dohme Corp. Inhibitors of AKT activity
KR20120034644A (ko) 2009-05-12 2012-04-12 알바니 몰레큘라 리써치, 인크. 아릴, 헤테로아릴, 및 헤테로사이클 치환된 테트라하이드로이소퀴놀린 및 이의 용도
CN102638982B (zh) 2009-05-12 2015-07-08 百时美施贵宝公司 (S)-7-([1,2,4]三唑并[1,5-a]吡啶-6-基)-4-(3,4-二氯苯基)-1,2,3,4-四氢异喹啉的晶型及其用途
CA2760837C (en) 2009-05-12 2018-04-03 Albany Molecular Research, Inc. 7-([1,2,4]triazolo[1,5-.alpha.]pyridin-6-yl)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydroisoquinoline and use thereof
WO2011046771A1 (en) 2009-10-14 2011-04-21 Schering Corporation SUBSTITUTED PIPERIDINES THAT INCREASE p53 ACTIVITY AND THE USES THEREOF
WO2011163330A1 (en) 2010-06-24 2011-12-29 Merck Sharp & Dohme Corp. Novel heterocyclic compounds as erk inhibitors
CA2805265A1 (en) 2010-08-02 2012-02-09 Merck Sharp & Dohme Corp. Rna interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (ctnnb1) gene expression using short interfering nucleic acid (sina)
WO2012024170A2 (en) 2010-08-17 2012-02-23 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF HEPATITIS B VIRUS (HBV) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
US8883801B2 (en) 2010-08-23 2014-11-11 Merck Sharp & Dohme Corp. Substituted pyrazolo[1,5-a]pyrimidines as mTOR inhibitors
US8946216B2 (en) 2010-09-01 2015-02-03 Merck Sharp & Dohme Corp. Indazole derivatives useful as ERK inhibitors
EP2615916B1 (en) 2010-09-16 2017-01-04 Merck Sharp & Dohme Corp. Fused pyrazole derivatives as novel erk inhibitors
WO2012058210A1 (en) 2010-10-29 2012-05-03 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACIDS (siNA)
WO2012087772A1 (en) 2010-12-21 2012-06-28 Schering Corporation Indazole derivatives useful as erk inhibitors
JP2014514321A (ja) 2011-04-21 2014-06-19 メルク・シャープ・アンド・ドーム・コーポレーション インスリン様増殖因子１受容体阻害剤
US9023865B2 (en) 2011-10-27 2015-05-05 Merck Sharp & Dohme Corp. Compounds that are ERK inhibitors
US20150299696A1 (en) 2012-05-02 2015-10-22 Sirna Therapeutics, Inc. SHORT INTERFERING NUCLEIC ACID (siNA) COMPOSITIONS
WO2014052563A2 (en) 2012-09-28 2014-04-03 Merck Sharp & Dohme Corp. Novel compounds that are erk inhibitors
MX363243B (es) 2012-11-28 2019-03-14 Merck Sharp & Dohme Composiciones para tratar cáncer y usos de dichas composiciones.
RU2690663C2 (ru) 2012-12-20 2019-06-05 Мерк Шарп И Доум Корп. Замещенные имидазопиридины в качестве ингибиторов hdm2
US9540377B2 (en) 2013-01-30 2017-01-10 Merck Sharp & Dohme Corp. 2,6,7,8 substituted purines as HDM2 inhibitors
US20160194368A1 (en) 2013-09-03 2016-07-07 Moderna Therapeutics, Inc. Circular polynucleotides
US10947234B2 (en) 2017-11-08 2021-03-16 Merck Sharp & Dohme Corp. PRMT5 inhibitors
WO2020033284A1 (en) 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Prmt5 inhibitors
EP3833668A4 (en) 2018-08-07 2022-05-11 Merck Sharp & Dohme Corp. PRMT5 INHIBITORS

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX18467A (es) * 1988-11-23 1993-07-01 Pfizer Agentes terapeuticos de quinuclidinas
HUT65771A (en) * 1991-05-22 1994-07-28 Pfizer Process for producing substituted 3-amino-quinuclidine derivatives and pharmaceutical compositions containing them
JP2719063B2 (ja) * 1991-05-22 1998-02-25 ファイザー製薬株式会社 置換３−アミノキヌクリジンｐ物質拮抗剤

Also Published As

Publication number Publication date
CA2146007A1 (en) 1994-05-11
HUT65831A (en) 1994-07-28
AU5141293A (en) 1994-05-24
JPH06135964A (ja) 1994-05-17
ES2202313T3 (es) 2004-04-01
WO1994010170A1 (en) 1994-05-11
HU9303051D0 (en) 1994-01-28
DK0665843T3 (da) 2003-12-01
ATE247113T1 (de) 2003-08-15
FI934752A0 (fi) 1993-10-27
CA2146007C (en) 1999-02-23
DE69333143T2 (de) 2004-02-26
JP2656700B2 (ja) 1997-09-24
DE69333143D1 (de) 2003-09-18
FI114637B (fi) 2004-11-30
IL107346A0 (en) 1994-01-25
EP0665843B1 (en) 2003-08-13
FI934752A (fi) 1994-04-29
EP0665843A1 (en) 1995-08-09
PT665843E (pt) 2003-12-31

Similar Documents

Publication Publication Date Title
MX9306704A (es) Quinuclidinas substituidas.
ES2160596T3 (es) Derivados de quinuclidina como antagonistas de la sustancia p.
HUP9600448A2 (hu) Naftilvegyületek, e vegyületeket tartalmazó gyógyszerkészítmények, eljárás előállításukra, intermedierjeik és alkalmazásuk
EP0395328A3 (en) Penylpyrimidone derivates and their use as therapeutic agents
EG20001A (en) Process for preparing of novel hydrox-amic acid and N-hydroxyurea derivatives and their use
ATE103812T1 (de) Zusammensetzung zur behandlung von ischaemischen stoerungen in organen.
NO810479L (no) Fremgangsmaate for fremstilling av terapeutisk aktive substituerte imidazolderivater
DE69413118D1 (de) Benzolsulfonamid-Derivate zur Behandlung der Blaseninstabilität
MX9707596A (es) Benzamidas, el uso de las mismas, composiciones que las contienen, para el tratamiento del transtorno neurodegenerativo, y procedimiento para la preparacion del mismo.
BR112023001060A2 (pt) Composto, composição farmacêutica, combinação, processo para fabricar uma composição farmacêutica, e, método de tratamento e/ou prevenção de um transtorno
UA66751C2 (en) Benzamides as medicament for treatment of neurodegenerative state, a method for the preparation thereof (variants), pharnaceutical composition for treatment of neurodegenerative states and a method for treatment
HUT34945A (en) Process for the production of new resorcionol-derivatives and of therapeutic prepartions containing them
ATE186912T1 (de) Carbamoylpyrrolidon-derivate zur behandlung von depressionen und cerebrovasculären störungen
ATE283834T1 (de) Phenantrenderivate mit medizinischer anwendung sowie dessen herstellungsverfahren